Abstract: Provided herein is an instrument delivery device for use with an intravenous catheter assembly. The instrument delivery device includes a housing having a proximal end portion and a distal end portion, with the housing including a first housing portion and a second housing portion arranged side-by-side and coupled together to define an inner volume. The instrument delivery device also includes an instrument movably received within the inner volume, a coupling device positioned at the distal end portion of the housing and configured to couple the housing to an access connector of an intravenous catheter assembly, and an advancement member configured to move relative to the housing to advance a distal end of the instrument beyond the distal end portion of the housing and into the intravenous catheter assembly. The housing comprises a visualization aid configured to improve visibility of the instrument within the inner volume of the housing.

Abstract: Provided herein is an instrument delivery device for use with an intravenous catheter assembly. The instrument delivery device includes a housing having a proximal end portion and a distal end portion and defining an inner volume, an instrument movably received within the inner volume, a coupling device positioned at the distal end portion of the housing and configured to couple the housing to an access connector of an intravenous catheter assembly, an advancement member configured to move relative to the housing to advance a distal end of the instrument beyond the distal end portion of the housing and into the intravenous catheter assembly, and a light generating element disposed at least partially within the housing and configured to generate light that enables visualization of the instrument.

Abstract: The invention relates inter alia to methods of producing sulfated oligosaccharide derivatives and intermediates thereof. The sulfated oligosaccharide derivatives may be represented by the following formula (I): [X]nY?ZR1R2Formula (I) wherein: X and Y are any D- or L-hexose or pentose, wherein each hydroxyl group not involved in a glycosidic linkage is substituted by a group W, and Y has an anomeric carbon atom; W is SO3M, and M is any pharmaceutically acceptable cation; n is an integer from 2 to 6; Z is O, and is linked to the anomeric carbon atom of Y; and R1R2 together form a lipophilic moiety.

Abstract: A modular crossover system includes one or more platforms, one or more platform guardrails attached to the platform, a plurality of towers supporting the one or more platforms, a plurality of stile assemblies attached to the platforms, or a combination of towers and stile assemblies. An optional fixed ladder may be attached to one of the platforms.

Abstract: A self-charging auxiliary power system is configured to be mounted on a vehicle and includes a hydraulic generator and at least one battery. The battery is electrically coupled to and operable to be charged by the hydraulic generator. A cooling system is operable to cool hydraulic fluid that drives the hydraulic generator. A housing protects the at least one battery.

Abstract: A system includes one or more processors configured to determine a discharge rate associated with discharging material from a hauling machine. In some examples, the system receives sensor data associated with a crushing machine configured to receive the material. Based on the sensor data, the system determines the discharge rate, to optimize the efficiency of the crushing machine. In some examples, the system determines the discharge rate based on input by an operator via a user interface. In some examples, the system determines an angular rate at which to raise a bed of the hauling machine to cause the material to be discharged at the discharge rate. Based on a determination to discharge material, the system causes the bed to be raised at the angular rate to discharge material. In some examples, the system may update the discharge rate based on additional sensor data and/or an additional operator input.

Abstract: A method of forming a twisted pair of wires for use with Ethernet-based networks. At least two wires are extruded with a cross-linked polyolefin insulating composition marketed under the registered trademark, EXRAD®. The wires are twisted together with a consistent lay length to form a cable. The cable is irradiated to become thermoset. Electrical properties of the extruded wire are controlled during the extrusion step and concentricity of the wire and surrounding insulation is also monitored and controlled. The cable can be jacketed to provide greater mechanical protection.

Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

Abstract: A liquid dispensing system is described comprising a universal refill of liquid and an emanation device; wherein the refill comprises: a housing having an inner volume and an outer surface; at least one reservoir in the inner volume of the housing for holding the liquid; at least one aperture in the housing sealed by a sealing means; and at least one wick provided on or connected to the outer surface of the housing, wherein said wick(s) is not extend to the inner volume of the housing; and wherein the emanation device is selected from: an emanation device configured to spray the liquid; an emanation device configured to evaporate the liquid by electrically powered means; an emanation device configured to evaporate the liquid by passive, non-electrically powered means; an emanation device configured to emanate the liquid by two or more of spraying the liquid, evaporating the liquid by electrically powered means and/or evaporating the liquid by passive, non-electrically powered means; characterised in that each

Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

Abstract: A universal refill of liquid containing one or more active materials is described wherein the refill comprises: a housing; at least one reservoir in the housing for holding the liquid; at least one aperture in the housing wherein the or each aperture is closed by a valve system comprising at least two valves wherein at least one of said valve(s) is configured to be automatically resealable when not being held open and at least one of said valves is provided in the form of an annular ring valve; and wherein the refill is configured to allow the liquid to be extracted by at least two different methods of liquid extraction. Systems comprising emanation devices and universal refills are also described.

Abstract: A device for emanating a liquid is described wherein the device is for use with a refill of liquid, wherein the device comprises: a housing with at least one exit port for emanated liquid therein; a hollow and elongate extraction limb having at least one capillary tube therein, said at least one capillary tube being open at one end to extract liquid from the refill and open at the other end to deposit said liquid on at least one wick provided only on an outer surface of a refill housing.

Abstract: A refill for a liquid wherein the refill comprises: a housing having an inner volume and an outer surface; at least one reservoir in the inner volume of the housing for holding the liquid; at least one aperture in the housing sealed by a sealing means; and at least one wick provided on or connected to the outer surface of the housing, wherein said wick(s) is not extend to the inner volume of the housing.

Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

Abstract: A peak flow measurement device comprises a hollow body (1) having an inlet (8) for receiving fluid and an outlet (3), wherein the inlet (8) and outlet (3) are spaced apart from each other, the cross-sectional area of the body being greater than the cross-sectional area of the outlet and wherein in use the device is oriented such that the inlet is above the outlet and the measured peak flow is proportional to the maximum height (11) of fluid within the body.

Abstract: An emanation device comprises an emanation material container (10), an emanation section (20) and emanation material level indication means (14,16); wherein, the emanation material level indication means (14, 16) comprises a light source (14), a light detector (16) and control means (not shown), wherein the light detector (16) is adapted to receive light from the light source (14) when a level of emanation material in the emanation material container (10) is at a first level and wherein the light detector (16) is adapted to receive substantially no light from the light source (14) when a level of emanation material in the emanation material container (10) is at a second level.

Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.